Payment overview · 2025
General Payments
$336.35
10 reported records · 9 companies
Healthcare provider profile · identity verified
Abdul Shaikh
Allopathic & Osteopathic Physicians|Internal Medicine · PLAINWELL, MI · NPI 1619088358
Verified facts
What the public records show
CMS Open Payments records show Abdul Shaikh received $336.35 in general payments during 2025 across 10 reported records.
Insulet Corporation accounted for 29.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Mounjaro, Ozempic.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Insulet Corporation | Unresolved — no canonical attribution shown | $99.42 | 29.6% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $65.09 | 19.4% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $41.00 | 12.2% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $26.87 | 8.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $23.70 | 7.0% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $22.16 | 6.6% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $20.12 | 6.0% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $19.56 | 5.8% | 1 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.43 | 5.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $336.35 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OMNIPOD Normalized: omnipod |
Device | Insulet Corporation | $99.42 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $65.09 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $41.00 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $26.87 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $23.70 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $23.70 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $22.16 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $20.12 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $20.12 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $19.56 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $19.56 | 1 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $18.43 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $15.07 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 93 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 78 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
61 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
78 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
93 | 29 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 500 | 142 |
| Gabapentin | Gabapentin | 390 | 87 |
| Amlodipine Besylate | Amlodipine Besylate | 302 | 81 |
| Levothyroxine Sodium | Levothyroxine Sodium | 273 | 75 |
| Omeprazole | Omeprazole | 246 | 73 |
| Lisinopril | Lisinopril | 245 | 77 |
| Metoprolol Succinate | Metoprolol Succinate | 227 | 70 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 222 | 44 |
| Alprazolam | Alprazolam | 215 | 38 |
| Metformin Hcl | Metformin Hcl | 180 | 53 |
| Citalopram Hbr | Citalopram Hydrobromide | 172 | 34 |
| Trazodone Hcl | Trazodone Hcl | 141 | 37 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 140 | 30 |
| Duloxetine Hcl | Duloxetine Hcl | 134 | 27 |
| Losartan Potassium | Losartan Potassium | 130 | 42 |
| Pantoprazole Sodium | Pantoprazole Sodium | 129 | 39 |
| Tamsulosin Hcl | Tamsulosin Hcl | 124 | 37 |
| Tramadol Hcl | Tramadol Hcl | 120 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 119 | 42 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 117 | 19 |
| Sertraline Hcl | Sertraline Hcl | 113 | 37 |
| Metformin Hcl Er | Metformin Hcl | 109 | 32 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 102 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 100 | 26 |
| Hydrochlorothiazide | Hydrochlorothiazide | 94 | 31 |
| Eliquis | Apixaban | 93 | 29 |
| Simvastatin | Simvastatin | 93 | 26 |
| Clonazepam | Clonazepam | 92 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 89 | 26 |
| Allopurinol | Allopurinol | 88 | 21 |
| Furosemide | Furosemide | 88 | 42 |
| Metoprolol Tartrate | Metoprolol Tartrate | 84 | 24 |
| Potassium Chloride | Potassium Chloride | 83 | 35 |
| Meloxicam | Meloxicam | 78 | 25 |
| Ozempic | Semaglutide | 78 | 16 |
| Warfarin Sodium | Warfarin Sodium | 77 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 76 | 22 |
| Montelukast Sodium | Montelukast Sodium | 74 | 21 |
| Ibandronate Sodium | Ibandronate Sodium | 72 | 17 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 69 | 13 |
| Ezetimibe | Ezetimibe | 67 | 14 |
| Prednisone | Prednisone | 66 | 43 |
| Carvedilol | Carvedilol | 62 | 21 |
| Januvia | Sitagliptin Phosphate | 61 | 15 |
| Jardiance | Empagliflozin | 61 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 61 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 57 | 21 |
| Alendronate Sodium | Alendronate Sodium | 55 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 53 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 53 | 19 |
| Glimepiride | Glimepiride | 51 | 14 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 51 | 14 |
| Aripiprazole | Aripiprazole | 50 | 18 |
| Spironolactone | Spironolactone | 48 | 17 |
| Xarelto | Rivaroxaban | 48 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 47 | 12 |
| Famotidine | Famotidine | 45 | 13 |
| Oxycodone Hcl | Oxycodone Hcl | 43 | suppressed |
| Bumetanide | Bumetanide | 41 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 41 | 11 |
| Buspirone Hcl | Buspirone Hcl | 40 | suppressed |
| Dulera | Mometasone/Formoterol | 40 | suppressed |
| Mirtazapine | Mirtazapine | 40 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 34 | suppressed |
| Memantine Hcl | Memantine Hcl | 34 | 11 |
| Topiramate | Topiramate | 34 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 33 | suppressed |
| Ibuprofen | Ibuprofen | 33 | suppressed |
| Dutasteride | Dutasteride | 32 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 32 | suppressed |
| Lovastatin | Lovastatin | 32 | suppressed |
| Mounjaro | Tirzepatide | 32 | suppressed |
| Novolog Flexpen | Insulin Aspart | 31 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 31 | suppressed |
| Atenolol | Atenolol | 30 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 30 | suppressed |
| Trulicity | Dulaglutide | 30 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 29 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 29 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 28 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 28 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 26 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 26 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 26 | suppressed |
| Pregabalin | Pregabalin | 26 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 26 | suppressed |
| Methadone Hcl | Methadone Hcl | 24 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 24 | suppressed |
| Azithromycin | Azithromycin | 22 | 22 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 20 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 20 | suppressed |
| Cephalexin | Cephalexin | 20 | 17 |
| Entresto | Sacubitril/Valsartan | 20 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 20 | suppressed |
| Nystatin | Nystatin | 20 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 20 | suppressed |
| Primidone | Primidone | 20 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 20 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Linzess | Linaclotide | 19 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 17 |
| Amiodarone Hcl | Amiodarone Hcl | 18 | suppressed |
| Fentanyl | Fentanyl | 18 | suppressed |
| Lamotrigine | Lamotrigine | 18 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Lorazepam | Lorazepam | 18 | suppressed |
| Bupropion Xl | Bupropion Hcl | 17 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 17 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 16 | suppressed |
| Finasteride | Finasteride | 16 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 15 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 15 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Xtampza Er | Oxycodone Myristate | 12 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $336.35 · 10 records | Insulet Corporation | CAPVAXIVE, Cologuard Collection Kit, ELIQUIS, FANAPT, GARDASIL 9, Korlym, MOUNJARO, NURTEC ODT, OMNIPOD, Ozempic, Qelbree, Rybelsus, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error